Exhibit 99.1 InMode Reports First Quarter 2024 Financial Results; Quarterly Revenue of $80.3M Represents 24% Year-Over-Year Decrease; Pro Forma Revenue (including new platform pre-orders not yet available) of $96M; Company Announces Share Repurchase Program of Up to 8.37 Million Shares; and Appoints New Chairman of the Board of Directors YOKNEAM, Israel, May 2, 2024 - InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financi ...

The market expects InMode (INMD) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on May 2, 2024, might help the stock move higher if these key numbers are better than ...

YOKNEAM, Israel, April 15, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, responded to the recent petition to the U.S. Patent & Trademark Office filed by BTL Industries, Inc., in which BTL asks the USPTO to conduct an Inter Partes Review of InMode's U.S. Patent No. 8,961,511.  Six months before BTL's petition, InMode sued BTL in the United States District Court for the Central District of California alleging that BTL's UltraFemme 360 and EmFemm ...

NEW YORK, April 13, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against InMode Ltd. ("InMode" or the "Company") (NASDAQ: INMD) and reminds investors of the April 15, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In InMode To Con ...

Expects Q1 Revenue Between $80.0M-$80.1M, Pro Forma Revenue (including new platform pre-orders) Between $95.7M- $95.8M, Decreases FY 2024 Guidance to $485M-$495M Conference call to be held on Thursday, May 2, 2024, at 8:30 a.m. Eastern Time YOKNEAM, Israel, April 9, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the first quarter of 2024 before the Nasdaq market opens on Thur ...

InMode Ltd. (NASDAQ:INMD) Q4 2023 Earnings Conference Call February 13, 2024 8:30 AM ET Company Participants Miri Segal - Investor Relations Moshe Mizrahy - Chairman, CEO and Co-Founder Michael Kreindel - Co-Founder and Chief Technology Officer Yair Malca - Chief Financial Officer Shakil Lakhani - President, North America Rafael Lickerman - VP of Finance Conference Call Participants Matt Miksic - Barclays Mike Sarcone - Jefferies Danielle Antalffy - UBS Mike Matson - Needham & Company Caitlin Cronin - Canac ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...

Revenue Performance - Fourth quarter 2023 revenue was $126.8 million, a decrease of 5.4% from $133.6 million in Q4 2022[6] - Full year 2023 revenue reached a record $492 million, representing an 8% year-over-year increase from $454.3 million in 2022[6] - Revenues for Q4 2023 were $126,781,000, a decrease of 5.9% compared to $133,571,000 in Q4 2022[36] - For the full year 2023, revenues reached $492,048,000, an increase of 8.3% from $454,271,000 in 2022[39] - International revenues increased by 18% year-over-year, contributing to overall revenue growth[6] Profitability - GAAP net income for Q4 2023 was $55.2 million, or $0.64 per diluted share, compared to $37.7 million, or $0.44 per diluted share in Q4 2022[10] - Non-GAAP net income for Q4 2023 was $61.5 million, or $0.71 per diluted share, down from $66.4 million, or $0.78 per diluted share in Q4 2022[10] - Net income for Q4 2023 increased to $55,165 thousand, a 46.3% rise from $37,708 thousand in Q4 2022[26] - Net income for Q4 2023 was $61,487,000, compared to $66,370,000 in Q4 2022, representing a decrease of 7.4%[36] - Net income for the year 2023 was $221,519,000, compared to $207,486,000 in 2022, reflecting an increase of 6.8%[39] Gross Margin - Gross margins for both GAAP and non-GAAP were 84% for Q4 2023, consistent with the previous year[8] - Gross profit for the year ended December 31, 2023, was $411,340 thousand, up 8.0% from $380,786 thousand in 2022[26] - Gross profit for Q4 2023 was $107,090,000, down from $113,122,000 in Q4 2022, reflecting a decline of 5.3%[36] - Gross profit for the year ended December 31, 2023, was $413,386,000, up from $382,703,000 in 2022, indicating an increase of 8.0%[39] - Non-GAAP gross margin for 2024 is projected to be between 83% and 85%[14] Operating Expenses - Operating expenses for the year increased to $215,680 thousand, up 17.9% from $182,932 thousand in 2022, primarily driven by sales and marketing expenses[26] - Operating expenses totaled $49,524,000 in Q4 2023, an increase of 7.5% from $46,076,000 in Q4 2022[36] - Operating expenses for the year were $194,126,000, a rise of 20.9% compared to $160,397,000 in 2022[39] Cash Position and Assets - As of December 31, 2023, the total cash position was $741.6 million, including cash and cash equivalents, marketable securities, and short-term bank deposits[11] - Cash and cash equivalents at the end of Q4 2023 were $144,411 thousand, compared to $97,540 thousand at the end of Q4 2022, reflecting a 47.9% increase[31] - Total assets as of December 31, 2023, were $863,286 thousand, up 34.1% from $644,409 thousand in 2022[28] - Total liabilities decreased to $75,914 thousand as of December 31, 2023, down from $89,791 thousand in 2022, a reduction of 15.5%[28] Future Outlook - The company plans to launch 2 new platforms in 2024 to enhance market share in minimally invasive aesthetics treatments[5] - Management expects 2024 revenue to be between $495 million and $505 million[14] - The company plans to continue investing in research and development, with R&D expenses for the year totaling $13,410 thousand, an increase from $12,425 thousand in 2022[26]

InMode (NASDAQ:INMD) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Miri Segal - Investor Relations Moshe Mizrahy - Chief Executive Officer and Chairman of Board of Directors Shakil Lakhani - President, North America Yair Malca - Chief Financial Officer Spero Theodorou - Chief Medical Officer Conference Call Participants Matt Miksic - Barclays Matthew Taylor - Jefferies Ryan Barocas - UBS Dane Reinhardt - Baird Mike Matson - Needham and Company Caitlin Cronin - Canaccord G ...

Exhibit 99.1 InMode Reports Third Quarter 2023 Financial Results; Quarterly Revenue of $123.1M Represents 2% Year-Over-Year Growth YOKNEAM, Israel, Nov. 2, 2023- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the third quarter ended September 30, 2023. Third Quarter 2023 Highlights: | U.S. GAAP Results | | | | --- | --- | --- | | (U.S. dollars in thousands, except for per share data) | | | | Q3 2023 ...